AbbVie's drug Humira is currently the best-selling medication on the planet, and it is approved to treat a wide range of diseases, including Crohn's Disease and ulcerative colitis. Recently, the company announced a partnership with a small biotech company called Galapagos to develop a JAK1 inhibitor for Crohn's Disease. In the following video, health-care analyst Max Macaluso discusses the details behind this deal and how this drug can potentially help the company maintain its lead in the autoimmune disease market in the coming years.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.
The article AbbVie's New Crohn's Disease Drug Candidate originally appeared on Fool.com.
Max Macaluso, Ph.D. and The Motley Fool have no position in any stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.